We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Antibacterial Resistance Revealed in Women with UTIs

By LabMedica International staff writers
Posted on 08 Sep 2017
Nearly 20% of women aged 15-29 are diagnosed with a urinary tract infection (UTI) and antibiotic resistance prolongs UTI treatment and resistance profiles vary regionally. More...
This regional variation is an important consideration in guiding empirical treatment selection.

Regional studies in the USA have identified tetracycline resistance in over a third of Ureaplasma spp. isolates, but no studies have evaluated antibiotic resistance levels in college-aged women with first-time UTI, which has been estimated at USD 3.5 billion in USA costs.

Scientists at the University of Florida (Gainesville, FL, USA) tested a panel of antibiotics and determined the minimum inhibitory concentrations (MICs) of Ureaplasma spp. and 10 Mycoplasma hominis isolates obtained from urine of college-aged women with first-time UTI. The study included 180 women with symptomatic first-time UTIs, along with 80 age-matched controls and 35 of the women had recurrent UTIs.

The investigators reported that low antibiotic resistance was found in this population of women with first-time UTI. Two U. parvum isolates were resistant: one to levofloxacin (MIC: 4 μg/mL) and one to tetracycline (MIC: 8 μg/mL). All M. hominis and U. urealyticum isolates were sensitive. For the Ureaplasma spp., MIC90s were highest against gentamicin (21 μg/mL) and lowest against doxycycline (0.25 μg/mL). When comparing MIC levels between Ureaplasma spp., U. urealyticum had significantly higher MICs against each antibiotic except doxycycline.

For resistant isolates, the genetic mechanisms of resistance were determined. Polymerase chain reaction (PCR) amplification identified tetM present in the tetracycline resistant isolate, and a S83W mutation within the parC gene of the quinolone resistant isolate. Mary B. Brown, PhD, a Professor in the Department of Infectious Diseases and Immunology, said, “To our knowledge, this is the first report of this specific genetic mutation in Ureaplasma in the USA, and only the third report anywhere in the world. Antibiotics like penicillin and the other β-lactamases that interfere with cell wall synthesis are totally useless against the Mollicutes.” The study was published on August 21, 2017, in the journal Antimicrobial Agents and Chemotherapy.

Related Links:
University of Florida


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.